

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

In the Claims:

Claims 1. - 34. (Cancelled)

35. (Currently Amended) A filter comprising an agent being capable of reducing or preventing tobacco smoke-associated loss of peroxidase activity in the aerodigestive tract of a subject, the filter being designed and configured so as to enable release of said agent therefrom when in use by the subject, wherein said agent is hydroxocobalamin.

36. (Original) The filter of claim 35, being designed and configured as a tobacco smoke filter.

37. (Cancelled)

38. (Currently Amended) A filter comprising an agent being capable of reducing or preventing tobacco smoke-associated death of cells in the aerodigestive tract of a subject, the filter being designed and configured so as to enable release of said agent therefrom when in use by the subject, wherein said agent is an iron chelator.

39. (Original) The filter of claim 38, wherein said cells are lymphocytes.

40. (Original) The filter of claim 38, being designed and configured as a tobacco smoke filter.

41. (Cancelled)

42. (Currently Amended) The filter of claim 38, wherein said agent is iron chelator comprises deferoxamine.

43. (Previously Amended) A filter comprising an iron chelator being capable of reducing or preventing tobacco smoke-associated death of cells in the

aerodigestive tract of a subject, the filter being designed and configured so as to enable release of said iron chelator therefrom when in use by the subject.

44. (Original) The filter of claim 43, wherein said cells are lymphocytes.

45. (Original) The filter of claim 43, being designed and configured as a tobacco smoke filter.

46. - 47. (Cancelled)

48. (Currently Amended) A filter comprising an agent being capable of reducing or preventing tobacco smoke-associated loss of peroxidase activity in the aerodigestive tract of a subject, the filter being designed and configured so as to enable physico-chemical interaction between said agent and said tobacco smoke when in use by the subject, wherein said agent is hydroxocobalamin.

49. (Original) The filter of claim 48, being designed and configured as a tobacco smoke filter.

50. - 51. (Cancelled)

52. (Currently Amended) A filter comprising an agent being capable of reducing or preventing tobacco smoke-associated death of cells in the aerodigestive tract of a subject, the filter being designed and configured so as to enable physico-chemical interaction between said agent and said tobacco smoke when in use by the subject, wherein said agent comprises an iron chelator.

53. (Original) The filter of claim 52, wherein said cells are lymphocytes.

54. (Original) The filter of claim 52, being designed and configured as a tobacco smoke filter.

55. (Cancelled)

56. (Currently Amended) The filter of claim 52, wherein said agent is iron chelator comprises deferoxamine.

57. (Previously Amended) A filter comprising an agent being capable of reducing or preventing tobacco smoke-associated death of cells in the aerodigestive tract of a subject, wherein said agent includes an iron chelator and whereas the filter is designed and configured so as to enable physico-chemical interaction between said agent and said tobacco smoke when in use by the subject.

58. (Original) The filter of claim 57, wherein said cells are lymphocytes.

59. (Original) The filter of claim 57, being designed and configured as a tobacco smoke filter.

60. - 94. (Cancelled)

95. (Previously Presented) The filter of claim 35, wherein said agent is capable of inactivating cyanide.

96. (Previously Presented) The filter of claim 43, wherein said iron chelator is deferoxamine.

97. (Previously Presented) The filter of claim 48, wherein said agent is capable of inactivating cyanide.

98. (Previously Presented) The filter of claim 38, wherein said agent is capable of preventing saliva mediated toxicity.

99. (Previously Presented) The filter of claim 57, wherein said iron chelator is deferoxamine.